These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 6423033)
1. Prostacyclin--powerful, yes: but is it useful? Mitchell JR Br Med J (Clin Res Ed); 1983 Dec; 287(6408):1824-6. PubMed ID: 6423033 [No Abstract] [Full Text] [Related]
2. Prostacyclin in vascular pathology--therapeutic possibilities. Gryglewski RJ; Szczeklik A Ann Clin Res; 1984; 16(5-6):253-61. PubMed ID: 6398663 [No Abstract] [Full Text] [Related]
4. Antithrombotic management with a stable prostacyclin analogue during extracorporeal circulation. Maurin N Contrib Nephrol; 1991; 93():205-9. PubMed ID: 1802582 [No Abstract] [Full Text] [Related]
5. Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility. Kerins DM; Murray R; FitzGerald GA Prog Hemost Thromb; 1991; 10():307-37. PubMed ID: 1848945 [No Abstract] [Full Text] [Related]
6. Clinical pharmacology and potential of prostacyclin. Lewis PJ; Dollery CT Br Med Bull; 1983 Jul; 39(3):281-4. PubMed ID: 6354353 [No Abstract] [Full Text] [Related]
7. Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD). Fitscha P; Tiso B; Krais T; Sinzinger H Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():450-4. PubMed ID: 2444079 [No Abstract] [Full Text] [Related]
8. Iloprost in peripheral vascular disease--platelet function and clinical outcome. Fitscha P; Tiso B; Sinzinger H Prog Clin Biol Res; 1987; 242():463-8. PubMed ID: 2444993 [No Abstract] [Full Text] [Related]
9. Monitoring of in-vivo platelet deposition in patients with peripheral vascular disease after different doses of prostaglandin I2 (PGI2). Strobl-Jäger E; Fitscha P; Kaliman J; Sinzinger H Prog Clin Biol Res; 1987; 242():403-7. PubMed ID: 3118387 [No Abstract] [Full Text] [Related]
10. Clinical benefit and prolongation of platelet half-life induced by CG 4203, a stable PGI2-analogue. Kaliman J; Fitscha P; Barth H; Sinzinger H Prog Clin Biol Res; 1987; 242():469-77. PubMed ID: 3313421 [No Abstract] [Full Text] [Related]
11. Use of prostacyclin in extracorporeal circulation. Ede RJ; Hughes RD; Williams R Int J Artif Organs; 1985 Nov; 8(6):297-300. PubMed ID: 3908327 [No Abstract] [Full Text] [Related]
12. Prostacyclin in severe peripheral vascular disease. de San Lazaro C; Colver AF; Parkin JM Arch Dis Child; 1985 Apr; 60(4):370-2. PubMed ID: 3890767 [TBL] [Abstract][Full Text] [Related]
17. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration. Kozek-Langenecker SA; Spiss CK; Michalek-Sauberer A; Felfernig M; Zimpfer M Crit Care Med; 2003 Mar; 31(3):864-8. PubMed ID: 12626998 [TBL] [Abstract][Full Text] [Related]
18. Some remarks on the complex behaviour of platelet function during and after prostacyclin treatment. Sinzinger H; Silberbauer K; Leithner C; Schwarz M Vasa; 1981; 10(4):348-9. PubMed ID: 7032112 [No Abstract] [Full Text] [Related]